The Experts below are selected from a list of 13974 Experts worldwide ranked by ideXlab platform

Jukka Jokinen - One of the best experts on this subject based on the ideXlab platform.

Arto A Palmu - One of the best experts on this subject based on the ideXlab platform.

Pekka J Nuorti - One of the best experts on this subject based on the ideXlab platform.

  • impact of national ten valent Pneumococcal Conjugate Vaccine program on reducing antimicrobial use and tympanostomy tube placements in finland
    Pediatric Infectious Disease Journal, 2017
    Co-Authors: Arto A Palmu, Hanna Rintakokko, Hanna Nohynek, Pekka J Nuorti, Jukka Jokinen
    Abstract:

    Background:Otitis media in young children is associated with major resource use including antimicrobial consumption and tympanostomy tube placements (TTPs). We evaluated the impact of 10-valent Pneumococcal Conjugate Vaccine (PCV10) introduction into the Finnish National Vaccination Programme (NVP)

  • health care utilization for pneumonia in young children after routine Pneumococcal Conjugate Vaccine use in the united states
    JAMA Pediatrics, 2007
    Co-Authors: Fangjun Zhou, Moe H Kyaw, Abigail Shefer, Carla A Winston, Pekka J Nuorti
    Abstract:

    Objective: To estimate the effect of 7-valent Pneumococcal Conjugate Vaccine (PCV7) on rates of pneumonia-related health care utilization and costs in children younger than 2 years. Design: Retrospective population study. Setting: Approximately 40 large employers each year, from 1997 to 2004. Participants: Enrollees in the MarketScan databases collected by Thomson Medstat. Main Exposure: Pneumococcal Conjugate Vaccine immunization program. Main Outcome Measures: Rates of International Classification of Diseases, Ninth Revision-coded hospitalizations and ambulatory visits due to all-cause and Pneumococcal pneumonia and their medical expenditures. Results: Comparing the rates in 2004 with those in the baseline period of 1997 to 1999 among children younger than 2 years, hospitalizations due to all-cause pneumonia declined from 11.5 to 5.5 per 1000 children (52.4% decline; P <.001) and ambulatory visits due to all-cause pneumonia declined from 99.3 to 58.5 per 1000 children (41.1% decline; P<.001). Rates of hospitalizations due to Pneumococcal pneumonia declined from 0.6 to 0.3 per 1000 children (57.6% decline; P<.001) and rates of ambulatory visits declined from 1.7 to 0.9 per 1000 children (46.9% decline; P <.001). Projecting from these data to the US population, the total estimated direct medical expenditures for all-cause pneumonia-related hospitalizations and ambulatory visits in young children were reduced from an annual average of $688.2 million during the period of 1997 to 1999 to $376.7 million in 2004 (45.3% decline and approximately $310 million decrease). Conclusions: In children younger than 2 years, the age group targeted for vaccination, pneumonia-related health care utilization in a privately insured population declined substantially following PCV7 introduction. These results suggest that PCV7 may play an important role in reducing the burden of pneumonia, resulting in major savings in medical care cost.

  • reduction of frequent otitis media and pressure equalizing tube insertions in children after introduction of Pneumococcal Conjugate Vaccine
    Pediatrics, 2007
    Co-Authors: Katherine A. Poehling, Carlos G Grijalva, Pekka J Nuorti, Stacey W. Martin, Peter G Szilagyi, Bonnie Lafleur, Ed Mitchel, Richard D Barth, Marie R Griffin
    Abstract:

    OBJECTIVE. Streptococcus pneumoniae is an important cause of otitis media in children. In this study we estimated the effect of routine childhood immunization with heptavalent Pneumococcal Conjugate Vaccine on frequent otitis media (3 episodes in 6 months or 4 episodes in 1 year) and pressure-equalizing tube insertions. PATIENTS AND METHODS. The study population included all children who were enrolled at birth in TennCare or selected upstate New York commercial insurance plans as of July 1998 and continuously followed until 5 years old, loss of health plan enrollment, study outcome, or end of the study. We compared the risk of developing frequent otitis media or having pressure-equalizing tube insertion for 4 birth cohorts (1998–1999, 1999–2000, 2000–2001, and 2001–2002) by using Cox regression analysis. We used data from the National Immunization Survey to estimate the heptavalent Pneumococcal Conjugate Vaccine uptake for children in these 4 birth cohorts in Tennessee and New York. RESULTS. The proportion of children in Tennessee and New York who received at least 3 doses of heptavalent Pneumococcal Conjugate Vaccine by 2 years of age increased from ≤1% for the 1998–1999 birth cohort to ∼75% for the 2000–2001 birth cohort. By age 2 years, 29% of Tennessee and New York children born in 2000–2001 had developed frequent otitis media, and 6% of each of these birth cohorts had pressure-equalizing tubes inserted. Comparing the 2000–2001 birth cohort to the 1998–1999 birth cohort, frequent otitis media declined by 17% and 28%, and pressure-equalizing tube insertions declined by 16% and 23% for Tennessee and New York children, respectively. For the 2000–2001 to the 2001–2002 birth cohort, frequent otitis media and pressure-equalizing tubes remained stable in New York but increased in Tennessee. CONCLUSIONS. After heptavalent Pneumococcal Conjugate Vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.

William C. Gruber - One of the best experts on this subject based on the ideXlab platform.

  • Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
    The Pediatric infectious disease journal, 2016
    Co-Authors: Fengcai Zhu, Mariano M. Young, Xin Zhou, Zhangjing Chen, Bing Yan, John Z. Liang, William C. Gruber
    Abstract:

    Background:Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) were compared with 7-valent Pneumococcal Conjugate Vaccine (PCV7) in Chinese infants.Methods:Healthy infants aged 2 months were randomized to a double-blind 3-dose infant series plus 1 toddler dose of PCV7 or PC

  • Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
    The Pediatric infectious disease journal, 2015
    Co-Authors: Takehiro Togashi, William C. Gruber, Kenji Okada, Masako Yamaji, Allison Thompson, Alejandra Gurtman, Mark Cutler, Masakazu Aizawa, Daniel A. Scott
    Abstract:

    Background:13-Valent Pneumococcal Conjugate Vaccine (PCV13) provides broader protection against Pneumococcal disease than 7-valent Pneumococcal Conjugate Vaccine (PCV7). This study performed in Japan compared the safety and immunogenicity of PCV13 with PCV7.Methods:Healthy Japanese infants received

  • immunogenicity and safety of 13 valent Pneumococcal Conjugate Vaccine in infants and toddlers
    Pediatrics, 2010
    Co-Authors: Sylvia H Yeh, William C. Gruber, Alejandra Gurtman, Kathrin U Jansen, David C Hurley, Stan L Block, Richard H Schwartz, Scott Patterson, Jack Love, Emilio A Emini
    Abstract:

    BACKGROUND: 7-Valent Pneumococcal Conjugate Vaccine (PCV7 [Prevnar, Wyeth Pharmaceuticals Inc, Philadelphia, PA], serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) is effective in preventing Vaccine-serotype Pneumococcal disease. 13-Valent Pneumococcal Conjugate Vaccine (PCV13) (PCV7 serotypes plus 1, 3, 5, 6A, 7F, and 19A) was designed to provide broader Pneumococcal disease coverage. We evaluated the immunogenicity and safety of PCV13 compared with PCV7. METHODS: Infants received PCV13 or PCV7 at ages 2, 4, 6, and 12 to 15 months with routine pediatric vaccinations. Pneumococcal anticapsular polysaccharide-binding immunoglobulin G responses and functional antiPneumococcal opsonophagocytic activity were assessed 1 month after dose 3, before the toddler dose, and 1 month after the toddler dose. Safety and tolerability were also assessed. RESULTS: For the 7 common serotypes, PCV13-elicited immunoglobulin G titers were noninferior to those elicited by PCV7, although PCV13 responses were generally somewhat lower. PCV13 also elicited functional opsonophagocytic activity comparable with that elicited by PCV7. For the 6 additional serotypes in PCV13, PCV13 elicited binding and functional antibody levels notably greater than those in PCV7 recipients. After PCV13 immunization, concordance between antipolysaccharide and opsonophagocytic responses was noted for all 13 serotypes. The PCV13 toddler dose resulted in higher immune responses compared with infant-series doses. Safety and tolerability were comparable; reactogenicity was generally mild. CONCLUSIONS: PCV13 will be as effective as PCV7 in the prevention of Pneumococcal disease caused by the 7 common serotypes and could provide expanded protection against the 6 additional serotypes. The PCV13 safety profile was comparable to that of PCV7.

  • safety tolerability and immunologic noninferiority of a 13 valent Pneumococcal Conjugate Vaccine compared to a 7 valent Pneumococcal Conjugate Vaccine given with routine pediatric vaccinations in germany
    Vaccine, 2010
    Co-Authors: Dorothee Kieninger, William C. Gruber, Kathrin Kueper, Katrin Steul, Christine Juergens, Norbert Ahlers, S Baker, Kathrin U Jansen, Carmel Devlin, Emilio A Emini
    Abstract:

    13-valent Pneumococcal Conjugate Vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional responses were generally comparable. For the 6 additional serotypes, PCV13-elicited IgG and functional OPA responses were notably greater than PCV7. The toddler dose boosted immune responses. Vaccines were comparable with regard to safety. PCV13 should be as effective as PCV7 in preventing Pneumococcal disease caused by the common serotypes and may provide protection against the additional serotypes.

Emilio A Emini - One of the best experts on this subject based on the ideXlab platform.

  • immunogenicity and safety of 13 valent Pneumococcal Conjugate Vaccine in infants and toddlers
    Pediatrics, 2010
    Co-Authors: Sylvia H Yeh, William C. Gruber, Alejandra Gurtman, Kathrin U Jansen, David C Hurley, Stan L Block, Richard H Schwartz, Scott Patterson, Jack Love, Emilio A Emini
    Abstract:

    BACKGROUND: 7-Valent Pneumococcal Conjugate Vaccine (PCV7 [Prevnar, Wyeth Pharmaceuticals Inc, Philadelphia, PA], serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) is effective in preventing Vaccine-serotype Pneumococcal disease. 13-Valent Pneumococcal Conjugate Vaccine (PCV13) (PCV7 serotypes plus 1, 3, 5, 6A, 7F, and 19A) was designed to provide broader Pneumococcal disease coverage. We evaluated the immunogenicity and safety of PCV13 compared with PCV7. METHODS: Infants received PCV13 or PCV7 at ages 2, 4, 6, and 12 to 15 months with routine pediatric vaccinations. Pneumococcal anticapsular polysaccharide-binding immunoglobulin G responses and functional antiPneumococcal opsonophagocytic activity were assessed 1 month after dose 3, before the toddler dose, and 1 month after the toddler dose. Safety and tolerability were also assessed. RESULTS: For the 7 common serotypes, PCV13-elicited immunoglobulin G titers were noninferior to those elicited by PCV7, although PCV13 responses were generally somewhat lower. PCV13 also elicited functional opsonophagocytic activity comparable with that elicited by PCV7. For the 6 additional serotypes in PCV13, PCV13 elicited binding and functional antibody levels notably greater than those in PCV7 recipients. After PCV13 immunization, concordance between antipolysaccharide and opsonophagocytic responses was noted for all 13 serotypes. The PCV13 toddler dose resulted in higher immune responses compared with infant-series doses. Safety and tolerability were comparable; reactogenicity was generally mild. CONCLUSIONS: PCV13 will be as effective as PCV7 in the prevention of Pneumococcal disease caused by the 7 common serotypes and could provide expanded protection against the 6 additional serotypes. The PCV13 safety profile was comparable to that of PCV7.

  • safety tolerability and immunologic noninferiority of a 13 valent Pneumococcal Conjugate Vaccine compared to a 7 valent Pneumococcal Conjugate Vaccine given with routine pediatric vaccinations in germany
    Vaccine, 2010
    Co-Authors: Dorothee Kieninger, William C. Gruber, Kathrin Kueper, Katrin Steul, Christine Juergens, Norbert Ahlers, S Baker, Kathrin U Jansen, Carmel Devlin, Emilio A Emini
    Abstract:

    13-valent Pneumococcal Conjugate Vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional responses were generally comparable. For the 6 additional serotypes, PCV13-elicited IgG and functional OPA responses were notably greater than PCV7. The toddler dose boosted immune responses. Vaccines were comparable with regard to safety. PCV13 should be as effective as PCV7 in preventing Pneumococcal disease caused by the common serotypes and may provide protection against the additional serotypes.